MUC16 and neoplasm: The SBS 5 signature was associated with the presence of periodontal disease (n = 8, 33.3% vs. n = 2, 8.3%; p = 0.004), higher recurrence risk (OR = 12.3, 95% CI: 1.3–109; p = 0.016), lower tumor burden (OR = 3.5, 95% CI: 1–11.9, p = 0.035), and absence of the MUC16 mutation (p = 0.015).